Skip to main navigation Skip to search Skip to main content

Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson’s disease

  • Eun Joo Shin
  • , Ji Hoon Jeong
  • , Yeonggwang Hwang
  • , Naveen Sharma
  • , Duy Khanh Dang
  • , Bao Trong Nguyen
  • , Seung Yeol Nah
  • , Choon Gon Jang
  • , Guoying Bing
  • , Toshitaka Nabeshima
  • , Hyoung Chun Kim

Research output: Contribution to journalReview articlepeer-review

26 Scopus citations

Abstract

Parkinson’s disease (PD) is a progressive neurodegenerative disease with a high prevalence, approximately 1 % in the elderly population. Numerous studies have demonstrated that methamphetamine (MA) intoxication caused the neurological deficits and nigrostriatal damage seen in Parkinsonian conditions, and subsequent rodent studies have found that neurotoxic binge administration of MA reproduced PD-like features, in terms of its symptomatology and pathology. Several anti-Parkinsonian medications have been shown to attenuate the motor impairments and dopaminergic damage induced by MA. In addition, it has been recognized that mitochondrial dysfunction, oxidative stress, pro-apoptosis, proteasomal/autophagic impairment, and neuroinflammation play important roles in inducing MA neurotoxicity. Importantly, MA neurotoxicity has been shown to share a common mechanism of dopaminergic toxicity with that of PD pathogenesis. This review describes the major findings on the neuropathological features and underlying neurotoxic mechanisms induced by MA and compares them with Parkinsonian pathogenesis. Taken together, it is suggested that neurotoxic binge-type administration of MA in rodents is a valid animal model for PD that may provide knowledge on the neuropathogenesis of PD.

Original languageEnglish
Pages (from-to)668-688
Number of pages21
JournalArchives of Pharmacal Research
Volume44
Issue number7
DOIs
StatePublished - Jul 2021

Bibliographical note

Publisher Copyright:
© 2021, The Pharmaceutical Society of Korea.

Funding

This study was supported by a Grant (#19182MFDS410) from the Korea Food and Drug Administration and by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science and ICT (#NRF-2019R1A2C4070161 and #NRF-2019R1I1A3A01063609), Republic of Korea. The English in this document has been checked by a professional English editor (Editage by CACTUS Communications Inc., Seoul, Republic of korea, www.editage.co.kr , https://app.editage.co.kr/orders/download-files/WQQNG_3 and https://app.editage.co.kr/orders/download-files/WQQNG_9 ).

FundersFunder number
National Research Foundation of Korea
Korea Food and Drug Administration
CACTUS Communications Inc.
Ministry of Science, ICT and Future Planning-2019R1A2C4070161, -2019R1I1A3A01063609
UK Industrial Decarbonization Research and Innovation Centre104553

    Keywords

    • Animal model
    • Dopaminergic neurotoxicity
    • Methamphetamine
    • Parkinson’s disease

    ASJC Scopus subject areas

    • Molecular Medicine
    • Drug Discovery
    • Organic Chemistry

    Fingerprint

    Dive into the research topics of 'Methamphetamine-induced dopaminergic neurotoxicity as a model of Parkinson’s disease'. Together they form a unique fingerprint.

    Cite this